Clinical significance of serum estradiol monitoring in women receiving adjuvant aromatase inhibitor for hormone receptor-positive early breast cancer.

MLA

Dai, Shuqin, et al. “Clinical Significance of Serum Estradiol Monitoring in Women Receiving Adjuvant Aromatase Inhibitor for Hormone Receptor-Positive Early Breast Cancer.” Breast (Edinburgh, Scotland), vol. 78, Sept. 2024, p. 103818. EBSCOhost, https://doi.org/10.1016/j.breast.2024.103818.

APA

Dai, S., Wu, X., Huang, X., Li, J., Wang, X., Wang, S., Tang, J., Shi, Y., Xie, X., Xu, F., Liu, P., Huang, J., Xie, X., An, X., Chen, M., Hong, R., Xia, W., Zheng, Q., Jiang, K., … Xue, C. (2024). Clinical significance of serum estradiol monitoring in women receiving adjuvant aromatase inhibitor for hormone receptor-positive early breast cancer. Breast (Edinburgh, Scotland), 78, 103818. https://doi.org/10.1016/j.breast.2024.103818

Chicago

Dai, Shuqin, Xingping Wu, Xuefang Huang, Jibin Li, Xi Wang, Shusen Wang, Jun Tang, et al. 2024. “Clinical Significance of Serum Estradiol Monitoring in Women Receiving Adjuvant Aromatase Inhibitor for Hormone Receptor-Positive Early Breast Cancer.” Breast (Edinburgh, Scotland) 78 (September): 103818. doi:10.1016/j.breast.2024.103818.